Bruce Sachais, MD, PhD

The focus of the Translational Research and Development Laboratory is to translate important scientific innovations into products and services to help patients suffering from blood diseases and/or otherwise in need of safe, effective blood transfusions. This newly created laboratory is working with other research, development and clinical laboratories within the New York Blood Center Enterprises (NYBCe) as well as partner start-up and biotechnology companies to create the future of Transfusion Medicine and develop novel therapies for hematology patients. Current projects focus on development of a novel treatment for Heparin Induced Thrombocytopenia, as well as methods to treat and improve blood and blood products for transfusion.

Partnership Opportunities

The TRDL offers development, contract for service, consulting, and wet diligence services.

Current TRDL services include:

• Blood component preparation
• Analysis of whole blood and blood components (RBCs, platelets, plasma, and white cells)
• Immunohematology
• Plasma and whole blood coagulation
• Microscopy
• Flow cytometry
• Other biological analyses

If you are interested in partnering with the TRDL, please contact [email protected]

Learn more about NYBC Ventures.

Funding Support

• NIH R42 HL123126  NYBC PI: Sachais 09/2016 – 06/2023 “Small Molecule Antagonists of PF4 for the treatment and prevention of HIT”
• NIH R44HL145783    Tabadadze (PI); Sachais (NYBC PI)  03/2019-02/2023 ” A closed system for pathogen reduction of red blood cells for transfusion”
• 75N92019D00037  Hod (PI); Sachais (NYBC PI)  04/2019-03/2026 Recipient Epidemiology and Donor Evaluation Study IV-P Domestic Hub (Federal Gov)

Education and Training